Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia
| dc.rights.license | open | en_US |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | CAMOU, Fabrice | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | TINEVEZ, Claire | |
| hal.structure.identifier | Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine] | |
| dc.contributor.author | BEGUET-YACHINE, Mathilde | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | BELLECAVE, Pantxika | |
| hal.structure.identifier | Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine] | |
| dc.contributor.author | RATIARISON, Diana | |
| hal.structure.identifier | CHU Bordeaux | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | TUMIOTTO, Camille | |
| hal.structure.identifier | Biothérapies des maladies génétiques et cancers | |
| hal.structure.identifier | Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine] | |
| dc.contributor.author | LAFARGE, Xavier | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | GUISSET, Olivier | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | MOURISSOUX, Gaelle | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | LAFON, Marie-Edith | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BONNET, Fabrice | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | ISSA, Nahema | |
| dc.date.accessioned | 2023-05-23T09:34:51Z | |
| dc.date.available | 2023-05-23T09:34:51Z | |
| dc.date.issued | 2021-05-03 | |
| dc.identifier.issn | 0146-6615 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/182256 | |
| dc.description.abstractEn | This study aims to assess the efficacy and safety of convalescent plasma therapy (CPT) in COVID-19 critically ill patients with protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia. A retrospective cohort study was conducted in intensive care unit (ICU). All patients with severe COVID-19 pneumonia for whom RNAemia remained positive more than 14 days after onset of the infection were included and given CPT. The primary objective was to evaluate SARS-CoV-2 RNAemia 7 days (D7) after CPT. A total of 14 patients were included and they received a median CPT volume of 828 ml (range: 817-960). CPT was administered in a median time of 14 days after ICU admission. At D7, 13/14 patients had negative SARS-CoV-2 blood PCR and one patient had negative blood PCR 11 days after CPT. At D7 and at D14, the clinical status was improved in 7/14 and 11/14 patients, respectively. The 28-day mortality rate was 14%. No CPT-related adverse effects had been reported. CPT is safe and may be efficient in patients with protracted RNAemia admitted in ICU for severe COVID-19 pneumonia. Randomized controlled trials are needed to confirm these results. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Combination therapy | |
| dc.subject.en | Disease control | |
| dc.subject.en | Generalized infection | |
| dc.subject.en | Pathogenesis | |
| dc.subject.en | SARS coronavirus | |
| dc.subject.en | Virus classification | |
| dc.title.en | Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/jmv.27032 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| bordeaux.journal | Journal of Medical Virology | en_US |
| bordeaux.page | Online ahead of print | en_US |
| bordeaux.hal.laboratories | MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234 | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.institution | Université de Bordeaux | |
| bordeaux.institution | INSERM | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | hal | |
| hal.identifier | hal-03278001 | |
| hal.version | 1 | |
| hal.export | false | |
| workflow.import.source | hal | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Medical%20Virology&rft.date=2021-05-03&rft.spage=Online%20ahead%20of%20print&rft.epage=Online%20ahead%20of%20print&rft.eissn=0146-6615&rft.issn=0146-6615&rft.au=CAMOU,%20Fabrice&TINEVEZ,%20Claire&BEGUET-YACHINE,%20Mathilde&BELLECAVE,%20Pantxika&RATIARISON,%20Diana&rft.genre=article |
